Literature DB >> 26433556

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Lori M Minasian1, Catherine M Tangen2, D Lawrence Wickerham3.   

Abstract

Large cancer prevention trials provide opportunities to collect a wide array of data and biospecimens at study entry and longitudinally, for a healthy, aging population without cancer. This provides an opportunity to use pre-diagnostic data and specimens to evaluate hypotheses about the initial development of cancer. We report on strides made by, and future possibilities for, the use of accessible biorepositories developed from precisely annotated samples obtained through large-scale National Cancer Institute (NCI)-sponsored cancer prevention clinical trials conducted by the NCI Cooperative Groups. These large cancer prevention studies, which have enrolled more than 80,000 volunteers, continue to contribute to our understanding of cancer development more than 10 years after they were closed. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26433556      PMCID: PMC4593316          DOI: 10.1053/j.seminoncol.2015.07.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  89 in total

1.  Evaluation of Medicare claims data to ascertain peripheral vascular events in the Women's Health Initiative.

Authors:  Matthew W Mell; Mary Pettinger; Lori Proulx-Burns; Susan R Heckbert; Matthew A Allison; Michael H Criqui; Mark A Hlatky; Dale R Burwen
Journal:  J Vasc Surg       Date:  2014-03-11       Impact factor: 4.268

2.  Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

Authors:  S M Lippman; J J Lee; D D Karp; E E Vokes; S E Benner; G E Goodman; F R Khuri; R Marks; R J Winn; W Fry; S L Graziano; D R Gandara; G Okawara; C L Woodhouse; B Williams; C Perez; H W Kim; R Lotan; J A Roth; W K Hong
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 13.506

3.  Adapting clinical trials networks to promote cancer prevention and control research.

Authors:  Bryan J Weiner; Martha M McKinney; William R Carpenter
Journal:  Cancer       Date:  2006-01-01       Impact factor: 6.860

4.  Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Authors:  J A Cauley; L Norton; M E Lippman; S Eckert; K A Krueger; D W Purdie; J Farrerons; A Karasik; D Mellstrom; K W Ng; J J Stepan; T J Powles; M Morrow; A Costa; S L Silfen; E L Walls; H Schmitt; D B Muchmore; V C Jordan; L G Ste-Marie
Journal:  Breast Cancer Res Treat       Date:  2001-01       Impact factor: 4.872

5.  Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  R Day; P A Ganz; J P Costantino; W M Cronin; D L Wickerham; B Fisher
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Authors:  Demetrius Albanes; Cathee Till; Eric A Klein; Phyllis J Goodman; Alison M Mondul; Stephanie J Weinstein; Philip R Taylor; Howard L Parnes; J Michael Gaziano; Xiaoling Song; Neil E Fleshner; Powel H Brown; Frank L Meyskens; Ian M Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2014-06-24

7.  Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.

Authors:  Jeannette M Schenk; Cathee A Till; Catherine M Tangen; Phyllis J Goodman; Xiaoling Song; Kathleen C Torkko; Alan R Kristal; Ulrike Peters; Marian L Neuhouser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08       Impact factor: 4.254

8.  Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

Authors:  William D Figg; Cindy H Chau; Douglas K Price; Cathee Till; Phyllis J Goodman; Yonggon Cho; Marileila Varella-Garcia; Juergen K V Reichardt; Catherine M Tangen; Robin J Leach; Adrie van Bokhoven; Ian M Thompson; M Scott Lucia
Journal:  Urology       Date:  2014-05-10       Impact factor: 2.649

9.  Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

Authors:  Mark E Sherman; Marion Piedmonte; Phuong L Mai; Olga B Ioffe; Brigitte M Ronnett; Linda Van Le; Iouri Ivanov; Maria C Bell; Stephanie V Blank; Paul DiSilvestro; Chad A Hamilton; Krishnansu S Tewari; Katie Wakeley; Noah D Kauff; S Diane Yamada; Gustavo Rodriguez; Steven J Skates; David S Alberts; Joan L Walker; Lori Minasian; Karen Lu; Mark H Greene
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544

10.  Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.

Authors:  Brian M Wolpin; Cosmeri Rizzato; Peter Kraft; Charles Kooperberg; Gloria M Petersen; Zhaoming Wang; Alan A Arslan; Laura Beane-Freeman; Paige M Bracci; Julie Buring; Federico Canzian; Eric J Duell; Steven Gallinger; Graham G Giles; Gary E Goodman; Phyllis J Goodman; Eric J Jacobs; Aruna Kamineni; Alison P Klein; Laurence N Kolonel; Matthew H Kulke; Donghui Li; Núria Malats; Sara H Olson; Harvey A Risch; Howard D Sesso; Kala Visvanathan; Emily White; Wei Zheng; Christian C Abnet; Demetrius Albanes; Gabriella Andreotti; Melissa A Austin; Richard Barfield; Daniela Basso; Sonja I Berndt; Marie-Christine Boutron-Ruault; Michelle Brotzman; Markus W Büchler; H Bas Bueno-de-Mesquita; Peter Bugert; Laurie Burdette; Daniele Campa; Neil E Caporaso; Gabriele Capurso; Charles Chung; Michelle Cotterchio; Eithne Costello; Joanne Elena; Niccola Funel; J Michael Gaziano; Nathalia A Giese; Edward L Giovannucci; Michael Goggins; Megan J Gorman; Myron Gross; Christopher A Haiman; Manal Hassan; Kathy J Helzlsouer; Brian E Henderson; Elizabeth A Holly; Nan Hu; David J Hunter; Federico Innocenti; Mazda Jenab; Rudolf Kaaks; Timothy J Key; Kay-Tee Khaw; Eric A Klein; Manolis Kogevinas; Vittorio Krogh; Juozas Kupcinskas; Robert C Kurtz; Andrea LaCroix; Maria T Landi; Stefano Landi; Loic Le Marchand; Andrea Mambrini; Satu Mannisto; Roger L Milne; Yusuke Nakamura; Ann L Oberg; Kouros Owzar; Alpa V Patel; Petra H M Peeters; Ulrike Peters; Raffaele Pezzilli; Ada Piepoli; Miquel Porta; Francisco X Real; Elio Riboli; Nathaniel Rothman; Aldo Scarpa; Xiao-Ou Shu; Debra T Silverman; Pavel Soucek; Malin Sund; Renata Talar-Wojnarowska; Philip R Taylor; George E Theodoropoulos; Mark Thornquist; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Pavel Vodicka; Jean Wactawski-Wende; Nicolas Wentzensen; Chen Wu; Herbert Yu; Kai Yu; Anne Zeleniuch-Jacquotte; Robert Hoover; Patricia Hartge; Charles Fuchs; Stephen J Chanock; Rachael S Stolzenberg-Solomon; Laufey T Amundadottir
Journal:  Nat Genet       Date:  2014-08-03       Impact factor: 41.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.